Zymeworks inc. (ZYME)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16
Cash flows from operating activities:
Net loss

-145,437

-36,556

-10,406

-33,809

Items not involving cash:
Depreciation and amortization of property and equipment

2,312

1,880

1,681

541

Amortization of intangible assets

3,113

1,750

1,058

484

Impairment on acquired IPR&D

768

-

1,536

768

Stock-based compensation (recovery) expense

48,996

13,441

3,429

4,291

Amortization of operating lease right-of-use assets

1,906

-

-

-

Deferred income tax expense

726

17

-15

-5,505

Change in fair value of contingent consideration

271

237

470

-

Change in fair value of warrant liabilities (note 10)

-

3,565

-2,450

808

Equity loss on investment

-

-

-

-98

Gain on fair value of equity investment

-

-

-

177

Accretion on long-term debt

-

-

248

576

Loss on debt extinguishment

-

-

-3,114

-

Unrealized foreign exchange (gain) loss

-504

48

254

954

Changes in non-cash operating working capital:
Accounts receivable

1,828

119

-2,409

592

SR&ED receivables

-

-

-

780

Prepaid expenses and other current assets

8,680

251

202

3,141

Accounts payable and accrued liabilities

21,572

3,684

-358

1,934

Operating lease liabilities

-795

-

-

-

Deferred revenue

-3,530

36,471

-

-

Income taxes payable

-299

140

-71

212

Net cash used in operating activities

-81,853

24,177

219

-35,246

Cash flows from financing activities:
Proceeds from initial public offering, net of issuance costs (note 11a)

-

-

55,791

-

Proceeds from subsequent public offerings, net of issuance costs (note 11a)

188,231

90,752

-

-

Issuance of preferred shares from private placement, net of issuance costs

-

-

-

58,860

Issuance of common shares on exercise of options (note 8e)

5,498

682

965

17

Issuance of common shares on exercise of warrants (note 10)

-

-

1,018

-

Issuance of common shares through employee stock purchase plan

598

233

-

-

Debt financing (note 9a)

-

-

-

6,953

Repayment of debt (note 10)

-

-

7,814

-

Deferred financing fees

650

225

-

1,046

Finance lease payments

16

11

9

7

Net cash provided by financing activities

193,661

91,431

49,951

64,777

Cash flows from investing activities:
Purchase of short-term investments

11,714

105,626

27,767

20,067

Acquisition of property and equipment

6,322

803

2,015

4,425

Acquisition of intangible assets

7,556

2,617

1,106

1,039

Cash acquired from Kairos, net of cash consideration

-

-

-

-78

Net cash (used in) provided by investing activities

-25,592

-109,046

-30,888

-25,453

Effect of exchange rate changes on cash and cash equivalents

30

-303

227

840

Net change in cash and cash equivalents

86,246

6,259

19,509

4,918

Supplemental disclosure of non-cash investing and financing items:
Leased assets obtained in exchange for operating lease liabilities

7,026

-

-

-

Share issue costs and deferred financing fees in accounts payable and accrued liabilities

-

-

-

910

Acquisition of property and equipment in accounts payable and accrued liabilities

607

382

123

2,055

Cashless exercise of warrants (note 10)

-

4,913

-

-

Class A Preferred Shares Warrant issued in connection with debt

-

-

-

3,266

Common Shares issued in connection with the Kairos acquisition

-

-

-

22,973